Phathom Pharmaceuticals (NASDAQ:PHAT) Research Coverage Started at Cantor Fitzgerald
Cantor Fitzgerald started coverage on shares of Phathom Pharmaceuticals (NASDAQ:PHAT – Free Report) in a research note released on Friday morning, MarketBeat.com reports. The firm issued an overweight rating and a $23.00 target price on the stock. A number of other analysts have also commented on the stock. Needham & Company LLC reiterated a “buy” […]
Cantor Fitzgerald started coverage on shares of Phathom Pharmaceuticals (NASDAQ:PHAT – Free Report) in a research note released on Friday morning, MarketBeat.com reports. The firm issued an overweight rating and a $23.00 target price on the stock. A number of other analysts have also commented on the stock. Needham & Company LLC reiterated a “buy” […]
